Prognostic significance of visit-to-visit variability, and maximum and minimum LDL cholesterol in diabetes mellitus
Chang-Sheng Sheng1, Ya Miao2, Lili Ding3
1Department of Cardiovascular Medicine, State Key Laboratory of Medical Genomics, Shanghai Key Laboratory of Hypertension, Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Road, 200025, Shanghai, China. scsheng2004@163.com.
Insights
High LDL-C variability predicts adverse outcomes in diabetes, independent of average LDL-C levels. Maintaining LDL-C below 70 mg/dL may indicate a better prognosis.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Syndrome
Background:
- Current dyslipidemia guidelines advocate for LDL-C goals below 70 mg/dL.
- The prognostic significance of LDL-C variability in diabetes remains under investigation.
Purpose of the Study:
- To investigate the prognostic significance of visit-to-visit LDL-C variability and extreme LDL-C values (minimum and maximum) during follow-up in patients with diabetes mellitus.
Main Methods:
- The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial data was analyzed.
- LDL-C variability was assessed using coefficient of variation (CV), variability independent of the mean (VIM), and average real variability (ARV).
- Multivariable Cox proportional hazards models were used to determine adjusted hazard ratios (HR) and 95% confidence intervals (CI).
Main Results:
- Fenofibrate therapy significantly reduced triglycerides and total cholesterol but not mean LDL-C compared to placebo.
- All LDL-C variability indices were associated with primary outcomes, total mortality, and cardiovascular mortality.
- Lower minimum LDL-C levels (≥70 mg/dL) during follow-up were linked to an increased risk of adverse outcomes.
Conclusions:
- Visit-to-visit LDL-C variability is a significant predictor of outcomes, irrespective of the mean LDL-C.
- Patients achieving LDL-C levels below 70 mg/dL during follow-up may experience a more favorable prognosis.
- The study identified NCT00000620 as the ClinicalTrials.gov identifier.
Background:
Current guidelines for dyslipidemia management recommend that the LDL-C goal be lower than 70 mg/dL. The present study investigated the prognostic significance of visit-to-visit variability in LDL-C, and minimum and maximum LDL-C during follow-up in diabetes mellitus.
Methods:
The risk of outcomes in relation to visit-to-visit LDL-C variability was investigated in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Lipid trial. LDL-C variability indices were coefficient of variation (CV), variability independent of the mean (VIM), and average real variability (ARV). Multivariable Cox proportional hazards models were employed to estimate the adjusted hazard ratio (HR) and 95% confidence interval (CI).
Results:
Compared with the placebo group (n=2667), the fenofibrate therapy group (n=2673) had a significantly (P<0.01) lower mean plasma triglyceride (152.5 vs. 178.6 mg/dL), and total cholesterol (158.3 vs.162.9 mg/dL) but a similar mean LDL-C during follow-up (88.2 vs. 88.6 mg/dL, P>0.05). All three variability indices were associated with primary outcome, total mortality and cardiovascular mortality both in the total population and in the fenofibrate therapy group but only with primary outcome in the placebo group. The minimum LDL-C but not the maximum during follow-up was significantly associated with various outcomes in the total population, fenofibrate therapy and placebo group. The minimum LDL-C during follow-up ≥70 mg/dL was associated with an increased risk for various outcomes.
Conclusions:
Visit-to-visit variability in LDL-C was a strong predictor of outcomes, independent of mean LDL-C. Patients with LDL-C controlled to less than 70 mg/dL during follow-up might have a benign prognosis. ClinicalTrials.gov number: NCT00000620.
Related Concept Videos
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Diabetes: Symptoms, Diagnosis, and Complications
Variability: Analysis
The range is a simple measure of variability, indicating the difference between the highest and...
Diabetes Mellitus: Type 2 and Gestational
Cholesterol: Significance and Regulation
Considering cholesterol and...
Regression Toward the Mean


